SCHEMBL15458866

SCHEMBL15458866

COC(=O)c1c(O)c(=O)nc(Cc2ccccc2)n1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.48
TBXA2R P21731 1/20 0.48
MAPK8 P45983 6/20 0.48
RNASEH1 O60930 1/20 0.46
LMNA P02545 2/20 0.43
AR P10275 1/20 0.43
PLA2G2A P14555 1/20 0.42
ADCY10 Q96PN6 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
MAPK9 P45984 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15458834 0.88 MAPK8 (0.43) DRD2TBXA2RMAPK8RNASEH1AR
SCHEMBL15458850 0.86 LMNA (0.48) RNASEH1LMNAALDH1A1MAPTGAA
SCHEMBL182807 0.80 MAPK8 (0.57) MAPK8LMNAARALDH1A1MAPT
SCHEMBL3363334 0.76 MAPK8 (0.53) MAPK8ARALDH1A1MAPTGAA
SCHEMBL15458889 0.74 FEN1 (0.39) LMNAPLA2G2AALDH1A1GAAPKM
SCHEMBL7886361 0.73 MAPK8 (0.48) MAPK8LMNAARALDH1A1MAPT
SCHEMBL23760001 0.73 MAPK8 (0.56) MAPK8PLA2G2AALDH1A1MAPTGAA
SCHEMBL20477211 0.71 ALDH1A1 (0.48) DRD2TBXA2RMAPK8PLA2G2AALDH1A1
SCHEMBL9280321 0.70 RNASEH1 (0.48) DRD2TBXA2RRNASEH1PLA2G2AADCY10
SCHEMBL22079307 0.70 RNASEH1 (0.57) RNASEH1ALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921388-B2 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2014-12-30 US disclosed
US-8921388-B2 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2014-12-30 US disclosed
US-20140038990-A1 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease SAVIRA PHARMACEUTICALS GMBH (AT) 2014-02-06 US disclosed
US-20140038990-A1 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease SAVIRA PHARMACEUTICALS GMBH (AT) 2014-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038990-A1 Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease DPYD, DHODH, ALAD DRD2 1822/4885TBXA2R 4371/4885MAPK8 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.